Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
J Infect Chemother ; 30(3): 250-254, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37844737

ABSTRACT

Systemic Capillary Leak Syndrome (SCLS) is a rare disease that causes severe distributive shock provoked by infection or vaccination. SCLS is clinically diagnosed by a triad of distributive shock, paradoxical hemoconcentration, and hypoalbuminemia. SCLS associated with coronavirus disease (COVID-19) in adults has not been reported yet in Japan. Case 1: A 61-year-old woman with fever, sore throat, headache, and muscle pain was admitted to our emergency department with suspected COVID-19. She had been diagnosed with SCLS 3 years earlier. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen and polymerase chain reaction (PCR) tests were negative at admission. She went into shock in the emergency department and was treated for septic shock. The following day, the SARS-CoV-2 PCR test was positive. She did not respond to fluid resuscitation and catecholamine and finally died. Case 2: A 58-year-old man was admitted to our hospital for de-saturation due to COVID-19. He got into shock on day 3. SCLS was suspected, and 5 g of intravenous immunoglobulin and 5% albumin were administered for sepsis treatment. He responded to the aggressive fluid therapy within 48 h and was finally discharged. COVID-19 can trigger SCLS, and early recognition of SCLS is crucial for survival. Primary care physicians should consider SCLS when they observe distributive shock and paradoxical hemoconcentration deviations from the natural course of COVID-19.


Subject(s)
COVID-19 , Capillary Leak Syndrome , Shock , Male , Adult , Female , Humans , Middle Aged , Capillary Leak Syndrome/complications , Capillary Leak Syndrome/diagnosis , Capillary Leak Syndrome/therapy , Japan , COVID-19/complications , COVID-19/diagnosis , SARS-CoV-2 , Shock/complications , Shock/diagnosis
2.
IDCases ; 31: e01656, 2023.
Article in English | MEDLINE | ID: mdl-36505907

ABSTRACT

Background: Non-serogroupable Neisseria meningitidis (N. meningitidis), the most common type of N. meningitidis in asymptomatic carriers, rarely causes infections. Most reported cases of infection are in patients with immunodeficiency, primarily complement deficiencies. Case presentation: A 54-year-old immunocompetent man was transferred to our hospital to treat severe coronavirus disease 2019 (COVID-19). The patient presented with cough producing a large amount of purulent sputum, which was considered an atypical presentation of COVID-19. Gram staining of the sputum revealed a large number of gram-negative diplococci phagocytosed by many neutrophils, and a diagnosis of bacterial pneumonia was established. The culture yielded non-serogroupable N. meningitidis, and the patient was diagnosed with non-serogroupable N. meningitidis pneumonia. Potential immunodeficiency was considered; however, testing including human immunodeficiency virus and complement factors showed no abnormalities. Conclusions: We report herein a rare case of non-serogroupable N. meningitidis pneumonia that occurred in an immunocompetent patient during the course of severe COVID-19. We consider impaired T cell function attributable to COVID-19 and dexamethasone administration may have triggered a transient immunosuppressive state and led to non-serogroupable N. meningitidis pneumonia.

3.
Int J Infect Dis ; 123: 176-179, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36057412

ABSTRACT

Disseminated toxoplasmosis associated with haemophagocytic lymphohistiocytosis (DT-HLH) is rare and difficult to diagnose compared to disseminated toxoplasmosis or HLH presenting alone. Because of the limited number of reported cases, the clinical characteristics and outcomes of DT-HLH are unknown. We report a case of DT-HLH in a human immunodeficiency virus (HIV)-infected patient who was successfully treated with early anti-toxoplasmic therapy and performed a comprehensive literature review. A 33-year-old Cameroonian woman was transferred to our hospital owing to HIV infection and encephalitis. Although she developed HLH, bone marrow biopsy did not reveal the cause. She was diagnosed as having DT-HLH via polymerase chain reaction testing of bone marrow biopsy tissue, blood, and cerebrospinal fluid. DT-HLH improved within the initial two weeks of treatment for toxoplasmosis (sulfamethoxazole-trimethoprim, trimethoprim 10 mg/kg/day and clindamycin 1,800 mg/day) before the introduction of antiretroviral therapy. To our knowledge, only eight cases of DT-HLH have been previously reported in the literature. Most patients died within three weeks of hospitalisation and were diagnosed by autopsy. Conversely, patients diagnosed antemortem were all treated and survived, including the currently reported patient. DT-HLH can lead to poor prognosis without early and proper treatment. Clinicians should consider toxoplasmosis in the differential diagnosis of HLH.


Subject(s)
HIV Infections , Lymphohistiocytosis, Hemophagocytic , Toxoplasmosis , Adult , Clindamycin/therapeutic use , Female , HIV , HIV Infections/complications , Humans , Lymphohistiocytosis, Hemophagocytic/complications , Lymphohistiocytosis, Hemophagocytic/diagnosis , Lymphohistiocytosis, Hemophagocytic/drug therapy , Sulfamethoxazole/therapeutic use , Toxoplasmosis/complications , Toxoplasmosis/diagnosis , Toxoplasmosis/drug therapy , Trimethoprim/therapeutic use
4.
Article in English | MEDLINE | ID: mdl-35494413

ABSTRACT

Objective: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in China and subsequently spread worldwide. In Japan, many clusters occurred during the first wave in 2020. We describe the investigation of an early outbreak in a Tokyo hospital. Methods: A COVID-19 outbreak occurred in two wards of the hospital from April to early May 2020. Confirmed cases were individuals with laboratory-confirmed SARS-CoV-2 infection linked to Wards A and B, and contacts were patients or workers in Wards A or B 2 weeks before the index cases developed symptoms. All contacts were tested, and cases were interviewed to determine the likely route of infection and inform the development of countermeasures to curb transmission. Results: There were 518 contacts, comprising 472 health-care workers (HCWs) and 46 patients, of whom 517 were tested. SARS-CoV-2 infection was confirmed in 42 individuals (30 HCWs and 12 patients). The proportions of SARS-CoV-2 infections in HCWs were highest among surgeons, nurses, nursing assistants and medical assistants. Several HCWs in these groups reported being in close proximity to one another while not wearing medical masks. Among HCWs, infection was thought to be associated with the use of a small break room and conference room. Discussion: Nosocomial SARS-CoV-2 infections occurred in two wards of a Tokyo hospital, affecting HCWs and patients. Not wearing masks was considered a key risk factor for infection during this outbreak; masks are now a mandated countermeasure to prevent the spread of SARS-CoV-2 infection in hospital settings.


Subject(s)
COVID-19 , Cross Infection , COVID-19/epidemiology , COVID-19/prevention & control , Cross Infection/epidemiology , Cross Infection/prevention & control , Disease Outbreaks/prevention & control , Hospitals , Humans , Japan/epidemiology , Pandemics/prevention & control , Patients' Rooms , SARS-CoV-2 , Tokyo/epidemiology
5.
BMC Infect Dis ; 22(1): 444, 2022 May 10.
Article in English | MEDLINE | ID: mdl-35538434

ABSTRACT

BACKGROUND: Several cases of coronavirus disease 2019 (COVID-19)-associated leukoencephalopathy have been reported. Although most cases involve hypoxia, the pathophysiological mechanism and neurologic outcomes of COVID-19-associated leukoencephalopathy remain unclear. CASE PRESENTATION: We report a case of COVID-19-associated leukoencephalopathy without severe hypoxia in a 65-year-old woman diagnosed with pyelonephritis. After the initiation of intravenous ceftriaxone, her fever resolved, but she developed an altered state of consciousness with abnormal behavior and, subsequently, a relapse fever. She was diagnosed with COVID-19 pneumonia and was intubated. Lung-protective ventilation with deep sedation and neuromuscular blockade were used for treatment. After cessation of sedative administration, her mental status remained at a Glasgow Coma Scale score of 3. COVID-19 was assumed to have caused leukoencephalopathy due to the absence of severe hypoxia or other potential causes. She subsequently showed gradual neurologic improvement. Three months after the COVID-19 diagnosis, she regained alertness, with a Glasgow Coma Scale score of 15. CONCLUSION: Clinicians should consider leukoencephalopathy in the differential diagnosis of consciousness disorders in patients with severe COVID-19, even in the absence of severe hypoxia. Gradual neurologic improvement can be expected in such cases.


Subject(s)
COVID-19 , Leukoencephalopathies , Aged , COVID-19/complications , COVID-19/diagnosis , COVID-19 Testing , Female , Humans , Hypoxia/etiology , Leukoencephalopathies/diagnosis , SARS-CoV-2
6.
J Infect Chemother ; 27(2): 291-295, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33121864

ABSTRACT

INTRODUCTION: We reported, in our previous study, a patient with coronavirus disease 2019 (COVID-19) who was successfully treated with extracorporeal membrane oxygenation. Data on clinical courses and outcomes of critically ill patients with COVID-19 in Japan are limited in the literature. This study aimed to describe the clinical courses and outcomes of critically ill patients with COVID-19 in Tokyo, Japan. METHODS: This is a single-center case series study. Patients with COVID-19 treated with mechanical ventilation (MV) were reviewed retrospectively. Data on baseline characteristics, in-hospital treatment, and outcomes were collected. RESULTS: Between February 2, 2020, and June 30, 2020, 14 critically ill patients with COVID-19 were treated with MV. Most patients were male and had comorbidities, especially hypertension or diabetes; 35.7% were overweight and 21.4% were obese. The majority of the patients had dyspnea on admission. The median duration of MV was 10.5 days, and the 28-day mortality rate was 35.7%. In the four patients with COVID-19 who died, the cause of death was respiratory failure. CONCLUSIONS: As in previous reports from other countries, the mortality rate of patients with COVID-19 requiring intensive care remains high in Tokyo. Further study on the appropriate timing of MV initiation and specific treatments for critically ill patients with COVID-19 is needed.


Subject(s)
COVID-19/epidemiology , Critical Illness/epidemiology , Respiration, Artificial/methods , Adult , Aged , Aged, 80 and over , COVID-19/mortality , COVID-19/therapy , Comorbidity , Critical Illness/mortality , Critical Illness/therapy , Diabetes Mellitus/epidemiology , Extracorporeal Membrane Oxygenation , Female , Humans , Hypertension/epidemiology , Japan , Male , Middle Aged , Obesity/epidemiology , Overweight/epidemiology , Respiratory Insufficiency/epidemiology , Retrospective Studies , SARS-CoV-2 , Tokyo , Treatment Outcome
7.
J Infect Chemother ; 25(7): 489-493, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30827859

ABSTRACT

BACKGROUND: Ebola virus disease (EVD) was endemic to Africa in 2014-2016. Supportive therapies have been shown to improve the outcome of EVD, and additional supportive therapy including blood transfusion therapy and external circulation could be needed in the event of a future global outbreak. However, pre-transfusion testing policies and guidelines have not yet been established in Japan. METHODS: We conducted a cross-sectional study of blood transfusion therapy for EVD patients at three designated hospitals for serious communicable diseases in Tokyo. In each hospital, we surveyed blood transfusion therapy policy, blood transfusion protocol, presence of a specialist in the department of transfusion medicine, facility capacity for pre-transfusion compatibility testing, and types of personal protective equipment available. RESULTS: One hospital had a cross-matched compatible blood transfusion policy, one had a cross-matched compatible blood transfusion policy only when the patient's ABO and RhD type is previously known, and the third had not created a policy. Two hospitals had a department of transfusion medicine. These two hospitals had a special testing unit for serious communicable diseases, while the other had a portable unit for testing. There were no major differences noted in available personal protective equipment. CONCLUSION: Policies and protocols differ among hospitals. The choice of blood transfusion policy and pre-transfusion testing is largely dependent on equipment and human resources. Further discussion is required to develop national guidelines for blood transfusion therapy in patients with serious communicable diseases, including countermeasures against complications and ethical issues related to the safety of patients and healthcare workers.


Subject(s)
Blood Transfusion/standards , Communicable Diseases/therapy , Hemorrhagic Fever, Ebola/therapy , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Transfusion Reaction/prevention & control , Communicable Diseases/transmission , Cross-Sectional Studies , Health Personnel/standards , Hemorrhagic Fever, Ebola/transmission , Humans , Policy , Practice Guidelines as Topic , Protective Clothing/standards , Tokyo
9.
J Infect Chemother ; 23(8): 567-571, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28385567

ABSTRACT

Gemella is a facultative anaerobic Gram-positive coccus and a rare cause of infective endocarditis (IE). Gram staining may eventually misidentify the organism, which tends to easily decolorize and manifest as either Gram-negative or Gram-variable. Commercial biochemical tests are often used to identify Gemella, but the methods they employ sometimes lack accuracy. A 52-year-old woman was diagnosed with Gemella taiwanensis IE after initial identification of the pathogen as Gemella haemolysans using biochemical tests combined with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). She was treated successfully with penicillin, gentamicin, and mitral valve replacement. To our knowledge, this is the first case of IE confirmed by 16S rRNA gene and groEL sequencing to have been caused by G. taiwanensis. The accurate diagnosis of rare or difficult-to-identify pathogens is a major challenge for clinical microbiological laboratories. The concurrent use of molecular methods could lead to the recognition of new or different pathogens.


Subject(s)
Endocarditis, Bacterial , Gemella , Gram-Positive Bacterial Infections , Anti-Bacterial Agents/therapeutic use , Bacterial Proteins/genetics , Chaperonin 60/genetics , DNA, Bacterial/analysis , DNA, Bacterial/genetics , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/microbiology , Female , Gemella/classification , Gemella/genetics , Gram-Positive Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Humans , Middle Aged , Phylogeny , RNA, Ribosomal, 16S/genetics
11.
J Infect Chemother ; 21(12): 873-6, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26386777

ABSTRACT

Streptococcal toxic shock syndrome (TSS) is a systemic illness usually caused in the setting of infection by group A Streptococcus (GAS). The primary infections are often invasive infections of the respiratory tract or necrotizing infections of the skin and soft tissue, but some infections occur without relevant focus. GAS vaginitis is a rare condition among adult women and is accordingly thought to be uncommon as a cause of streptococcal TSS. Here we report the cases of two postmenopausal women with streptococcal TSS secondary to GAS vaginitis, one aged 55 and one aged 60. Both came to our emergency department with complaints or symptoms of abdominal pain, fever, hypotension, and multi-organ failure. In both cases, the relevant factor associated with streptococcal infection was a recent episode of GAS vaginitis. Both underwent fluid management and 14 days of antibiotic treatment and fully recovered without complications. Vaginitis was likely to be the primary infectious trigger of TSS in these two cases. Intrauterine device insertion, endometrial biopsy, and post-partum state have all been previously reported in TSS patients, and the female genital tract has been described as a portal of entry. GAS vaginitis warrants appropriate treatment as it may progress to severe systemic infection as described.


Subject(s)
Shock, Septic/diagnosis , Shock, Septic/microbiology , Staphylococcal Infections/diagnosis , Streptococcus pyogenes/isolation & purification , Vaginosis, Bacterial/diagnosis , Female , Humans , Intraabdominal Infections/diagnosis , Intraabdominal Infections/drug therapy , Intraabdominal Infections/microbiology , Middle Aged , Shock, Septic/drug therapy , Staphylococcal Infections/drug therapy , Streptococcus pyogenes/drug effects , Vaginosis, Bacterial/drug therapy
12.
J Travel Med ; 22(1): 64-6, 2015.
Article in English | MEDLINE | ID: mdl-25159130

ABSTRACT

Hemophagocytic syndrome (HPS) can develop as a complication of dengue in rare cases, but its relationship with dengue is not well known. We report a case of dengue-associated HPS with liver involvement and coagulopathy. The patient, a Japanese female traveler who had recently returned from Thailand, had severe complications of dengue infection, but she recovered fully with symptomatic treatment.


Subject(s)
Dengue/complications , Dengue/diagnosis , Lymphohistiocytosis, Hemophagocytic/diagnosis , Travel , Adult , Asian People , Dengue/drug therapy , Diagnosis, Differential , Female , Humans , Lymphohistiocytosis, Hemophagocytic/complications , Thailand
13.
Chin J Traumatol ; 18(6): 360-2, 2015.
Article in English | MEDLINE | ID: mdl-26917029

ABSTRACT

Most mediastinal abscesses result from infections after thoracotomy, esophageal perforation or pene- trating chest trauma. This disease is rarely caused by closed blunt chest trauma. All previously reported such cases after closed blunt chest trauma presented with hematoma and sternal osteomyelitis resulting from sternal fracture. Here we report a 15-year-old sumo wrestler who presented with an anterior mediastinal abscess without any mediastinal fracture. The mediastinal abscess resulted from the hematogenous spread of Staphylococcus aureus to a hematoma that might have been caused by a closed blunt chest trauma incurred during sumo wrestling exercises.


Subject(s)
Abscess/microbiology , Abscess/therapy , Mediastinal Diseases/microbiology , Mediastinal Diseases/therapy , Staphylococcal Infections/microbiology , Staphylococcal Infections/therapy , Thoracic Injuries/microbiology , Thoracic Injuries/therapy , Wounds, Nonpenetrating/microbiology , Wounds, Nonpenetrating/therapy , Wrestling/injuries , Abscess/diagnosis , Adolescent , Anti-Bacterial Agents/therapeutic use , Combined Modality Therapy , Debridement , Diagnosis, Differential , Drainage , Humans , Magnetic Resonance Imaging , Male , Mediastinal Diseases/diagnosis , Staphylococcal Infections/diagnosis , Thoracic Injuries/diagnosis , Tomography, X-Ray Computed , Wounds, Nonpenetrating/diagnosis
14.
Parasitol Int ; 63(5): 698-700, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24929036

ABSTRACT

Subjective adverse reactions to metronidazole were analyzed in 111 patients with amebiasis. Metronidazole was administered to 36 patients at a daily dose of 2250 mg and 75 patients at daily doses lower than 2250 mg. The reactions reported included nausea without vomiting in 11 (9.9%) patients, nausea with vomiting in 2 (1.8%), dysgeusia in 2 (1.8%), diarrhea in 1 (0.9%), headache in 1 (0.9%), numbness in 1 (0.9%), dizziness in 1 (0.9%), urticaria in 1 (0.9%), exanthema in 1 (0.9%), and discomfort in 1 (0.9%). Nausea was reported by 28% (10/36) of the patients receiving metronidazole at a daily dose of 2250 mg and 4% (3/75) of the patients receiving lower daily doses. The duration of the metronidazole administration in days was not associated with the appearance of nausea. No life-threatening adverse reactions were identified, and good clinical therapeutic effects were observed in 96% (107/111) of the patients. While metronidazole appears to be a safe anti-protozoal agent for patients with amebiasis, our results indicate that a daily metronidazole dose of 2250 mg is excessive for amebiasis, as it often induces nausea.


Subject(s)
Amebiasis/drug therapy , Antiprotozoal Agents/adverse effects , Antiprotozoal Agents/therapeutic use , Metronidazole/adverse effects , Metronidazole/therapeutic use , Antiprotozoal Agents/administration & dosage , Humans , Metronidazole/administration & dosage
16.
J Infect Chemother ; 20(4): 278-81, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24486170

ABSTRACT

Leptospirosis is not a major disease in urban areas of Japan. We describe a 49-year-old man with leptospirosis, who lived in an urban area and had no history of living in endemic area of leptospirosis. As he worked at a fish market infested with rats, he was suspected of having contracted leptospirosis and received antimicrobial agent treatment. Serum and urinary tests confirmed the diagnosis of leptospirosis. Although it took six days from the onset until treatment initiation, the patient improved in response to receiving ceftriaxone for seven days. Analyzing past reports of Japanese patients with leptospirosis who had no history of overseas travel, we identified 90 patients with courses similar to that of our patient, and the period from onset to treatment initiation was about six days on average (described in 46 cases). Health care providers as well as patients need to recognize that even people with no history of being in an endemic area of leptospirosis may still be at risk of developing this disease depending on occupations and activities.


Subject(s)
Leptospirosis/diagnosis , Leptospirosis/drug therapy , Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Humans , Japan , Leptospirosis/pathology , Male , Middle Aged
17.
Intern Med ; 53(2): 155-8, 2014.
Article in English | MEDLINE | ID: mdl-24429458

ABSTRACT

We herein report the case of 41-year-old homosexual man who presented to our hospital with typical acute retroviral syndrome. Complications of bilateral facial nerve palsy and appendicitis appeared eight days after admission. The bilateral facial nerve palsy spontaneously recovered one month later; however, the appendicitis required surgical intervention. To our knowledge, this is the first reported case of appendicitis related to acute retroviral syndrome.


Subject(s)
AIDS-Associated Nephropathy/etiology , Appendicitis/etiology , Facial Nerve Diseases/etiology , Facial Paralysis/etiology , HIV Infections/complications , Acute Disease , Adult , Appendicitis/surgery , Emergencies , HIV Infections/diagnosis , Humans , Male , Meningitis, Aseptic/etiology
18.
Article in English | MEDLINE | ID: mdl-23682445

ABSTRACT

In Japan azithromycin (AZM) has been used to treat enteric fever caused by bacteria with resistance to fluoroquinolones; however, the dose, length of treatment and effectiveness of AZM among Japanese patients with enteric fever is unclear. We studied 5 Japanese adults and 1 Japanese child with enteric fever (4 had typhoid fever and 2 had paratyphoid fever) who were treated with oral AZM. The treatment regimens were: 1,000 mg as a single or in 2 divided doses on the 1st day, followed by 500 mg as a single dose daily for 5-6 additional days, or 500 mg as a single dose daily for 10 days. The minimum inhibitory concentrations (MICs) for AZM against 5 causative organisms were investigated with an E-test. Good clinical results were observed in the 5 adult patients but treatment failure was seen in the 1 child patient with typhoid fever; no adverse reactions were found. MICs of AZM were 4 microg/ml against S. Typhi in 2 patients, 8 microg/ml against S. Typhi in 2 patients, and 32 microg/ml against S. Paratyphi A in 1 patient. Our findings indicate AZM may be a reasonable choice for treatment of Japanese adult patients with enteric fever.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Paratyphoid Fever/drug therapy , Typhoid Fever/drug therapy , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Azithromycin/administration & dosage , Azithromycin/adverse effects , Child , Dose-Response Relationship, Drug , Female , Humans , Japan , Male , Microbial Sensitivity Tests
19.
Am J Trop Med Hyg ; 89(1): 58-62, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23629930

ABSTRACT

We report disseminated cysticercosis concurrent with taeniasis in a 31-year-old male Japanese, who had visited India three times and stayed for 1 month each time during the previous 1 year. The patient presented increasing numbers of subcutaneous nodules and expelled proglottids, although numerous cysts were also found in the brain in imaging findings, though no neurological symptoms were observed. Histopathological and serological findings strongly indicated cysticercosis. We found taeniid eggs in his stool by microscopic examination and revealed them as the Indian haplotype of Taenia solium by mitochondrial DNA analysis. We concluded that disseminated cysticercosis was caused by the secondary autoinfection with eggs released from the tapeworm carrier himself. After confirming the absence of adult worms in the intestine by copro-polymerase chain reaction, the patient was successfully treated with albendazole at a dose of 15 mg/kg/day for 28 days. Subcutaneous and intracranial lesions had completely disappeared by the end of the treatment period.


Subject(s)
Cysticercosis/etiology , Taeniasis/etiology , Travel , Adult , Animals , Brain/diagnostic imaging , Brain/parasitology , Cysticercosis/diagnosis , Cysticercosis/parasitology , Cysticercosis/pathology , DNA, Helminth/genetics , Feces/parasitology , Humans , India/epidemiology , Japan/ethnology , Male , Neurocysticercosis/diagnosis , Neurocysticercosis/etiology , Neurocysticercosis/parasitology , Neurocysticercosis/pathology , Neuroimaging , Polymerase Chain Reaction , Taenia solium , Taeniasis/diagnosis , Taeniasis/parasitology , Taeniasis/pathology , Tomography, X-Ray Computed
20.
Int J Infect Dis ; 17(8): e656-7, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23618773

ABSTRACT

Eight Japanese adult patients infected with Taenia asiatica were treated with a single 600 mg dose of praziquantel. The patients' body weights ranged from 47 to 87 kg (mean 67.1±12.7 kg). All patients expelled the strobila after taking praziquantel, and all of them were free from proglottids the day after praziquantel administration, hence all patients were considered to be cured. No side effects due to praziquantel were noted. Although the number of patients is small, our results indicate that praziquantel is a drug of choice for the treatment of taeniasis asiatica and that a single dose of 7-13 mg/kg (9.3±1.9 mg/kg) is effective.


Subject(s)
Anthelmintics/therapeutic use , Praziquantel/therapeutic use , Taeniasis/drug therapy , Adult , Aged , Anthelmintics/administration & dosage , Female , Humans , Male , Middle Aged , Praziquantel/administration & dosage , Taeniasis/diagnosis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...